NeoStem (AMEX: NBS) [click on preceding link for the Company' s News Room website] is an innovator and leader in the pre-disease collection, processing and long-term storage of adult stem cells for the general population to use in future medical applications that is expanding into research, medical tourism, and China for the commercialization of regenerative medicine and other stem cell applications. In late October, NeoStem completed its acquisition of China Biopharmaceuticals, which resulted in a controlling 51% interest in Suzhou Erye Pharmaceuticals (Erye) and established three business segments for the Company (US + China stem cells and China pharmaceuticals focused on antibiotics and active pharmaceutical ingredients).

1.) NeoStem (US) includes an exclusive worldwide license to VSELs, a strong IP sourcing network for innovative stem cell / pharmaceutical products and AMEX listing for the stock in addition to its position in the domestic market as a leading adult stem cell banking network.

2.) Erye is a high-growth pharmaceutical manufacturer in China with a strong core business / profitable revenue base amidst booming demand and growth in the Chinese market.

3.) NeoStem (China) has strong support from the Chinese government for commercialization of cosmetic / regenerative medicine applications which will also expedite the process of US development as the Company becomes a vertically integrated stem cell operation in a permissive regulatory environment that includes strong government support. NeoStem plans to leverage the R&D conducted in China to fast-track the U.S. FDA approval process.